Regenesis

Company Overview

Snapshot

Founded in February 2023, Regenesis operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing its innovative cartilage regeneration technology.

Business overview

Regenesis is a biomedical startup dedicated to revolutionizing the treatment of cartilage lesions. The company's core technology involves a unique biocompatible structure designed to enhance in situ cartilage regeneration through a minimally invasive procedure. This platform can be adapted for various medical conditions associated with cartilage damage, including hip and ankle lesions and Osteoarthritis (OA). Regenesis operates within the Health Tech & Life Sciences sector, specifically focusing on Pharma & Medical Biotechnology and Biomaterials & Tissue Engineering.

Company Intelligence Q&A

What is Regenesis's primary focus?

Regenesis is a biomedical startup focused on cartilage regeneration through electrical stimulations, aiming to treat cartilage lesions with a minimally invasive procedure.

When was Regenesis founded?

Regenesis was founded in February 2023.

What is the core technology behind Regenesis's platform?

The core technology is based on a unique biocompatible structure designed to be applied directly or indirectly to damaged areas for tissue regeneration.

What medical conditions does Regenesis's platform address?

The platform can be adopted for various medical conditions associated with cartilage damage, including hip and ankle lesions and Osteoarthritis (OA).

Does Regenesis hold any patents?

Yes, Regenesis holds a patent for its technology.